Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Schwann cell-derived exosomal vesicles are nanoscale extracellular vesicles (exosomes) secreted by Schwann cells—the myelinating glia of the peripheral nervous system. These vesicles range from 30–150 nm in diameter and contain a variety of bioactive molecules including miRNAs, mRNAs, proteins, and lipids. They play a crucial role in intercellular communication and have demonstrated significant therapeutic potential for tissue regeneration and repair—particularly in neurological injuries such as spinal cord injury (SCI), traumatic brain injury (TBI), and peripheral nerve damage[1][2][5][6]. Schwann cell-derived exosomal vesicles promote axonal regeneration by modulating cellular processes like proliferation, differentiation, angiogenesis, neuroprotection, and inflammation reduction[2][4][5]. Their small size allows them to cross the blood-brain barrier efficiently with low immunogenicity compared to whole-cell therapies. Additionally, they can be engineered for targeted delivery or loaded with therapeutic agents[6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on schwann cell-derived exosomal vesicles.